Clinical Trial

Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

Study acronym: CSA
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-30 -> 2026-12-31 2026-07-21
minor Completion pushed: 2026-12-31 -> 2027-06-30 2026-07-21
Trial Details
NCT Number NCT04118387
Lead Sponsor VA Office of Research and Development
Conditions Sleep Disordered Breathing, Able Bodied
Enrollment 200 participants
Start Date 2021-01-07
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-20